DIP Episode 452 - NMS and Malignant Hyperthermia (vs Serotonin Syndrome)

Source / episode info

• Episode: 452
• Title: Divine Intervention Episode 452: NMS and Malignant Hyperthermia (vs Serotonin Syndrome)
• Published: 2023-04-18
• Source: Episode page

One-liner

This episode compares Neuroleptic Malignant Syndrome (NMS) and Malignant Hyperthermia (MH), both presenting with rigidity and hypermetabolic states, while contrasting them sharply with Serotonin Syndrome (SS) based on underlying triggers, specific lab abnormalities ({K}^{+}, {PO}_{4}^{3-}), and neuromuscular signs (rigidity vs. hyperreflexia).

High-yield summary

• NMS: Characterized by severe muscle rigidity, altered mental status, fever, and lactic acidosis; often triggered by D2 receptor antagonists (anti-psychotics) or withdrawal of dopamine agonists.
• MH: A genetically inherited condition involving a mutation in the ryanodine receptor ({Ca}^{2+} channel); triggered by volatile anesthetics (e.g., sevoflurane, halothane) or succinylcholine; leads to massive {Ca}^{2+} release and hypermetabolism.
• MH Lab Triad: Due to muscle breakdown (rhabdomyolysis), MH patients often present with hyperkalemia, hyperphosphatemia, and subsequent hypocalcemia.
• Differential Diagnosis: The key differentiator is neuromuscular signs: NMS/MH cause rigidity and hypokinesis, whereas Serotonin Syndrome causes hyperreflexia and clonus.
• Treatment Cornerstone: Both MH and NMS can be treated with a ryanodine receptor antagonist, Dantrolene, which inhibits excessive calcium release.

Learning objectives

• Differentiate the clinical presentation (neuromuscular signs, lab abnormalities) among NMS, MH, and SS.
• Identify the specific triggers for Malignant Hyperthermia (volatile anesthetics, succinylcholine).
• Understand the underlying molecular defect in MH related to the ryanodine receptor.
• Recognize that dopamine agonists are both a potential cause and sometimes a treatment for NMS.
• Correlate muscle breakdown products (\text{K}^{+}, \text{PO}_{4}^{3-}, myoglobin) with severe hypermetabolic states like MH.

Board exam buzzwords

Rapid review table

Board-speak -> diagnosis

Differential diagnosis / distinguishing features

Malignant Hyperthermia vs Serotonin Syndrome

NMS vs Serotonin Syndrome

Management pearls

• MH Management: Immediate cessation of all triggering agents (anesthetics/succinylcholine). Administration of Dantrolene is the definitive treatment. Aggressive cooling, IV fluids, and monitoring for rhabdomyolysis are mandatory.
• NMS Management: Supportive care (cooling, hydration) and muscle relaxants if needed. If D2 blockade is suspected, consider administering a dopamine agonist (e.g., bromocriptine). Dantrolene may be used if rigidity is refractory to standard measures.
• Serotonin Syndrome Management: Discontinuation of offending agents. Supportive care including cooling and benzodiazepines for agitation/seizures. In severe cases, cyproheptadine (a 5-HT antagonist) may be administered.
• Monitoring in Crisis: Due to the risk of rhabdomyolysis in MH, continuous monitoring of \text{CK}, electrolytes (\text{K}^{+}, \text{Ca}^{2+}, \text{PO}_{4}^{3-}), and urine output is critical.

Don't miss

Integration & clinical reasoning

• Pharmacology Integration: Understanding D2 receptor blockade (anti-psychotics -> NMS) and calcium channel dysfunction (MH -> Dantrolene) demonstrates mastery of multiple drug classes and cellular mechanisms.
• Anesthesia Integration: Recognizing the specific class of agents that trigger MH (volatile anesthetics, succinylcholine) is essential for safe practice and board performance.
• Metabolic Integration: The cascade of electrolyte abnormalities in MH (\text{Hyper K} -> \text{Hyper P} -> \text{Hyp Ca}) links muscle pathology directly to systemic metabolic derangement.

OMM / COMLEX integration

• Standard emergency management for any hypermetabolic crisis (MH/NMS) takes priority: immediate cooling, IV fluids, and supportive care are paramount. OMT should only be considered adjunctive after stabilization of airway, breathing, and circulation.
• The recognition of a severe metabolic derangement (lactic acidosis, electrolyte imbalance) requires systemic support; this is critical for any patient presenting with altered mental status in the ED setting.

Concept connections / cross-references

• For detailed information on the pharmacology of antipsychotics and dopamine receptors, review [Episode 12].
• The general principles of managing hypermetabolic states are related to concepts discussed in [Episode 405] (e.g., heat stroke/hyperthermia).

High-yield association table

Key terms glossary

Study optimization

Question pattern recognition

• Pattern: Anesthesia + Rigidity/Fever -> Malignant Hyperthermia. Always suspect MH when a patient undergoing general anesthesia develops hypermetabolic signs, especially if volatile anesthetics are used.
• Pattern: Anti-psychotic use + Rigidity/Hyperthermia -> NMS. Consider D2 receptor blockade as the primary mechanism; check for dopamine agonist withdrawal history.
• Pattern: Hyperreflexia + Clonus + Serotonergic Drugs -> Serotonin Syndrome. The presence of hyperreflexia is the most reliable clue to differentiate SS from MH/NMS rigidity.

Test yourself

Common mistakes to avoid

Common traps